Financial Performance - YUPELRI achieved all-time high U.S. net sales of $71.4 million in Q3 2025, a 15% increase year-over-year driven by 6% customer demand growth [4]. - Total revenue for Q3 2025 was $20.0 million, with Viatris collaboration revenue increasing by 19% compared to Q3 2024 [13]. - Net income for Q3 2025 was $3.6 million, compared to a net loss of $12.7 million in Q3 2024, benefiting from a $6.5 million income tax benefit [17]. - Non-GAAP net income from operations was $2.3 million in Q3 2025, compared to a non-GAAP net loss of $2.9 million in Q3 2024 [17]. - Total revenue for Q3 2025 was $19,990,000, an increase of 18.5% compared to $16,868,000 in Q3 2024 [36]. - YUPELRI net sales recorded by Viatris for Q3 2025 were $71,363,000, up from $62,189,000 in Q3 2024, reflecting a growth of 17.5% [36]. - The company reported a net income of $3,615,000 for Q3 2025, compared to a net loss of $12,698,000 in Q3 2024, marking a significant turnaround [36]. - Non-GAAP net income for Q3 2025 was $2,260,000, compared to a loss of $2,897,000 in Q3 2024 [38]. Cash and Assets - Cash, cash equivalents, and marketable securities totaled $332.7 million as of September 30, 2025, with no debt [17]. - Cash and cash equivalents increased to $329,680,000 as of September 30, 2025, up from $88,350,000 at the end of 2024 [33]. - Total current assets rose to $354,697,000 as of September 30, 2025, compared to $161,067,000 at the end of 2024 [33]. - Shareholders' equity increased to $232,681,000 as of September 30, 2025, compared to $175,545,000 at the end of 2024 [33]. - The company has a future contingent milestone and royalty asset valued at $144,200,000 as of December 31, 2024 [33]. Research and Development - Research and Development expenses for Q3 2025 were $8.1 million, down from $9.3 million in Q3 2024 [13]. - Research and development expenses for Q3 2025 were $8,112,000, a decrease from $9,268,000 in Q3 2024 [36]. - The open-label portion of the pivotal Phase 3 CYPRESS study of ampreloxetine is complete, with topline results expected in Q1 2026 [6]. - The company plans to host a virtual Key Opinion Leader event on December 8, 2025, to discuss ampreloxetine's potential in treating neurogenic orthostatic hypotension [9]. Future Projections - The company is on track to exceed full year 2025 global net sales of approximately $3.4 billion, requiring $471 million in Q4 2025 to trigger a $50 million milestone from Royalty Pharma [12]. - Year-to-date sales of TRELEGY are on track to achieve a $50 million milestone in 2025, with global net sales of approximately $2.9 billion, up 13% year-over-year [7]. Expenses - Selling, general and administrative expenses increased to $18,333,000 in Q3 2025 from $16,875,000 in Q3 2024 [36].

Core Insights - Theravance Biopharma reported strong third-quarter results, achieving record net sales for YUPELRI and reaching non-GAAP breakeven, indicating financial and operational discipline [2][4][11] - The company is advancing ampreloxetine towards pivotal Phase 3 CYPRESS study topline results expected in Q1 2026, with a focus on addressing unmet needs in multiple system atrophy patients [2][3][15] Operational Highlights - YUPELRI net sales reached an all-time high of $71.4 million, a 15% increase year-over-year, driven by a 6% growth in customer demand and improved net pricing [4][5] - The open-label portion of the pivotal Phase 3 CYPRESS study for ampreloxetine is complete, with topline results anticipated in Q1 2026 [4][11] - The company plans to host a virtual Key Opinion Leader event on December 8, 2025, to discuss ampreloxetine's potential in treating neurogenic orthostatic hypotension [5][11] Financial Performance - Total revenue for Q3 2025 was $20.0 million, with Viatris collaboration revenue increasing by 19% compared to Q3 2024 [11][31] - R&D expenses for Q3 2025 were $8.1 million, down from $9.3 million in the same period in 2024, while SG&A expenses rose to $18.3 million from $16.9 million [11][31] - Net income for Q3 2025 was $3.6 million, a significant improvement from a net loss of $12.7 million in Q3 2024, aided by a $6.5 million income tax benefit [11][33] Strategic Initiatives - The company is preparing for an expedited NDA submission for ampreloxetine, contingent on supportive data from the ongoing study [5][15] - Theravance Biopharma continues to focus on disciplined capital allocation and returning excess cash to shareholders, with a Strategic Review Committee assessing strategic alternatives [18][20]

Core Viewpoint - Theravance Biopharma is set to present its clinical development program for ampreloxetine, a potential treatment for neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA), at the upcoming International Symposium on the Autonomic Nervous System [1][2]. Company Presentations - The company will have one platform presentation and three poster presentations at the symposium, focusing on the efficacy and methodologies related to ampreloxetine [1][2]. - The platform presentation will highlight results from the REDWOOD trial, showcasing durable symptomatic benefits of ampreloxetine in MSA patients [2]. - The three poster presentations will cover topics such as the impact of ampreloxetine on supine hypertension, retention strategies in rare disease clinical trials, and enrollment strategies in a Phase III trial for MSA-related nOH [2]. About Ampreloxetine - Ampreloxetine is an investigational, once-daily norepinephrine reuptake inhibitor aimed at treating symptomatic nOH in MSA patients [2][8]. - The treatment has shown an increase in norepinephrine levels and a favorable impact on blood pressure, with no worsening of supine hypertension reported [2]. - The company has received Orphan Drug Designation for ampreloxetine in the U.S. and plans to file a New Drug Application (NDA) if the ongoing Phase 3 CYPRESS study yields positive results [2]. Phase 3 Studies - The CYPRESS study is a registrational Phase 3 trial evaluating the efficacy and durability of ampreloxetine in MSA patients with symptomatic nOH after 20 weeks of treatment [3]. - The primary endpoint is the change in the Orthostatic Hypotension Symptom Assessment (OHSA) composite score [3]. - The REDWOOD study previously indicated that the benefits of ampreloxetine were particularly significant in MSA patients, with a 72% reduction in the odds of treatment failure compared to placebo [5]. Disease Context - Multiple system atrophy (MSA) is a progressive brain disorder affecting movement and balance, with approximately 50,000 patients in the U.S. [6]. - 70-90% of MSA patients experience symptomatic nOH, which is characterized by a significant drop in blood pressure upon standing [6][7]. - Neurogenic orthostatic hypotension (nOH) can lead to debilitating symptoms, including dizziness and fainting, severely impacting patients' quality of life [7].

Core Insights - Theravance Biopharma, Inc. will report its Q3 2025 financial results and provide a business update on November 10, 2025, after market close [1] - A conference call and webcast will be held on the same day at 5:00 pm EST [2] Company Overview - Theravance Biopharma focuses on delivering impactful medicines, leveraging decades of expertise [3] - The company has developed YUPELRI (revefenacin), an FDA-approved inhalation solution for chronic obstructive pulmonary disease (COPD) [3] - Ampreloxetine, a late-stage investigational drug, is being developed for neurogenic orthostatic hypotension in patients with Multiple System Atrophy, potentially becoming a first-in-class therapy [3]

Core Insights - Theravance Biopharma has launched a disease education campaign titled "Power in the Periphery" aimed at enhancing the understanding of neurogenic orthostatic hypotension (nOH) related to Multiple System Atrophy (MSA) [1][2] - The campaign was introduced at the International Congress of Parkinson's Disease and Movement Disorders, emphasizing the company's commitment to educating healthcare professionals about the complexities of nOH [2] Company Overview - Theravance Biopharma focuses on transforming the treatment landscape for specialty respiratory and neurologic diseases through innovative medicine development [6] Disease Context - Multiple System Atrophy (MSA) is a progressive brain disorder affecting movement and balance, with approximately 50,000 patients in the US, where 70-90% experience nOH symptoms [4] - Neurogenic orthostatic hypotension (nOH) is characterized by a significant drop in blood pressure upon standing, leading to debilitating symptoms such as dizziness and fainting [5]

Core Insights - Theravance Biopharma will present new analyses on YUPELRI at the CHEST 2025 annual meeting, highlighting its effectiveness in reducing exacerbations in COPD patients [1][2] Company Overview - Theravance Biopharma focuses on delivering impactful medicines, with YUPELRI (revefenacin) approved for the maintenance treatment of COPD [3] - The company is also developing Ampreloxetine, a potential first-in-class therapy for neurogenic orthostatic hypotension in patients with Multiple System Atrophy [3] Research Findings - A retrospective analysis showed that patients adherent to YUPELRI had significantly fewer exacerbations and lower healthcare costs compared to non-adherent patients [2][6] - Post-hoc analyses from a Phase 3 safety study indicated that YUPELRI's exacerbation profile over one year is at least as effective as tiotropium [2][6] Presentation Details - The presentations at CHEST 2025 include: - "Exacerbation Rates in COPD Patients: A Retrospective Analysis of the Nebulized Once Daily Long-Acting Muscarinic Antagonist Revefenacin in a 52-Week Safety Study" by Edmund J Moran, Ph.D. on October 21, 2025 [2] - "Adherence to Revefenacin Associated with Reductions in Exacerbations and Healthcare Costs Following a COPD-Related Hospitalization" by Grace Leung, MPH on October 21, 2025 [2]

Company Overview - Theravance Biopharma's shares have increased by approximately 9.8% since the last earnings report, outperforming the S&P 500 [1] - The company reported a narrower than expected adjusted net loss of 8 cents per share for Q2 2025, compared to the Zacks Consensus Estimate of a loss of 14 cents [3] - Total revenues for Q2 2025 reached $26.2 million, significantly exceeding the Zacks Consensus Estimate of $17 million, and representing an 83.2% year-over-year increase [4] Revenue Breakdown - The revenue growth was driven by increased collaboration revenues from partner Viatris and licensing revenues [4] - Collaboration revenues from Viatris related to Yupelri sales amounted to $18.7 million, reflecting a 31% year-over-year increase [5] - Theravance received a milestone payment of $7.5 million from Viatris following the approval of Yupelri in China [5] Expense Analysis - Research and development expenses (excluding share-based compensation) totaled $9.5 million, an increase of nearly 8% from the previous year [6] - Selling, general and administrative expenses (excluding share-based compensation) rose approximately 16.4% year-over-year to $12.8 million [6] - As of June 30, 2025, the company had cash, cash equivalents, and marketable securities worth $338.8 million, up from $130.9 million as of March 31, 2025 [6] Financial Guidance - Theravance reaffirmed its financial guidance for 2025, expecting adjusted R&D expenses in the range of $32-$38 million and adjusted SG&A expenses between $50 million and $60 million [7] - The company anticipates share-based compensation expenses of $18-$20 million in 2025 and expects adjusted losses and cash burn to be similar to 2024 levels [7] Market Sentiment - There has been a positive trend in fresh estimates, with the consensus estimate shifting by 36.84% recently [8] - Theravance holds a Growth Score of A but has a lower Momentum Score of C, with an overall VGM Score of A [10] - The stock has a Zacks Rank of 3 (Hold), indicating an expectation of an in-line return in the coming months [11] Industry Comparison - Theravance operates within the Zacks Medical - Drugs industry, where another player, United Therapeutics, has seen a 28% gain over the past month [12] - United Therapeutics reported revenues of $798.6 million for the last quarter, reflecting an 11.7% year-over-year increase, with an EPS of $6.41 compared to $5.85 a year ago [12]

Theravance Biopharma Conference Call Summary Company Overview - **Company**: Theravance Biopharma (NasdaqGM:TBPH) - **Key Products**: Ampreloxetine, YUPELRI - **Financial Position**: Over $300 million in cash, no debt, $175 million in near-term milestones expected with high probability of receipt [2][2] Core Product Insights Ampreloxetine - **Target Indication**: Rare neurological condition, multiple system atrophy (MSA) with neurogenic orthostatic hypotension (NOH) - **Patient Population**: Approximately 40,000 patients in the U.S. with MSA and NOH, with 66% to 75% experiencing significant symptoms [2][15] - **Clinical Development**: Phase 3 study completed enrollment; data expected in Q1 2026 [1][2] - **Mechanism of Action**: Addresses autonomic failure by improving blood pressure regulation, enabling patients to ambulate and improve quality of life [5][11] - **Market Opportunity**: Claims analysis suggests about 50,000 MSA patients in the U.S., with 80% having NOH [16][15] YUPELRI - **Current Performance**: Continued growth with a 22% increase in net sales year-over-year; $40 to $50 million in free cash flow annually [28][28] - **Market Strategy**: Focus on transitioning care from hospital to home, maximizing patient persistence on therapy [27][29] - **International Expansion**: Recently approved in China, with a passive interest from Theravance; expected launch likely in 2026 [30][30] Competitive Landscape - **Current Treatments**: Existing options like droxidopa and midodrine have limitations in efficacy and duration; ampreloxetine aims to provide a more durable solution [20][20] - **Regulatory Considerations**: Ampreloxetine does not have the same safety concerns (e.g., supine hypertension) as existing treatments [25][20] Commercial Strategy - **Pre-launch Activities**: Direct management of the CYPRESS study to build relationships with physicians and understand market needs [13][14] - **Resource Allocation**: Focused and deliberate capital investment strategy for the launch of ampreloxetine, contingent on successful data readout [24][24] - **Sales Approach**: Tailored strategies for rare disease markets, emphasizing close relationships with treatment centers [18][19] Financial Outlook - **Break-even Status**: The company is nearing cash flow break-even, with expectations to maintain this through data readout [28][28] - **Investment Strategy**: Future capital commitments will be made only when confident in regulatory success and market readiness [24][24] Additional Insights - **Patient Support**: Emphasis on providing comprehensive support for patients, including medical, pharmacologic, and access components [18][18] - **Market Research**: Ongoing efforts to refine understanding of the MSA NOH market to optimize resource allocation [19][19]

Company Announcement - Theravance Biopharma, Inc. will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York City on September 9, 2025 [1] - CEO Rick Winningham will engage in a Fireside Chat during the event at 1:30 PM EDT [1] Investor Engagement - Management will host in-person meetings during the conference, and interested investors are encouraged to contact their H.C. Wainwright representative for meeting requests [1] Company Overview - Theravance Biopharma focuses on delivering impactful medicines, with FDA-approved YUPELRI® for chronic obstructive pulmonary disease (COPD) [3] - The company is developing Ampreloxetine, a late-stage investigational therapy for neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), which has the potential to be a first-in-class treatment [3] - Theravance Biopharma is committed to creating and driving shareholder value [3]

Core Insights - Theravance Biopharma has completed enrollment in the pivotal Phase 3 CYPRESS study for ampreloxetine, targeting symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA) [1][3][5] - nOH affects approximately 80% of MSA patients, leading to severe symptoms and a lack of effective treatment options [1][8] - The CYPRESS study aims to evaluate the efficacy and safety of ampreloxetine, with topline data expected in Q1 2026 [3][5] Company Overview - Theravance Biopharma focuses on developing innovative therapies, including ampreloxetine, a selective norepinephrine reuptake inhibitor for nOH in MSA patients [4][9] - The company has received Orphan Drug Designation for ampreloxetine in the U.S., highlighting the unmet medical need in this patient population [5][9] Study Details - The CYPRESS study is a global, randomized-withdrawal trial assessing ampreloxetine's impact on nOH symptoms, with a primary endpoint of change in the Orthostatic Hypotension Symptom Assessment (OHSA) composite score [2][6] - The study includes a 12-week open-label phase followed by an 8-week randomized withdrawal phase [2][6] Market Context - There are approximately 40,000 patients in the U.S. suffering from symptomatic nOH due to MSA, indicating a significant market opportunity for effective treatments [2][5] - Current therapies for nOH often fail to provide lasting relief and have safety concerns, underscoring the need for new solutions like ampreloxetine [2][3]